全文获取类型
收费全文 | 8814篇 |
免费 | 407篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 103篇 |
儿科学 | 138篇 |
妇产科学 | 83篇 |
基础医学 | 1163篇 |
口腔科学 | 134篇 |
临床医学 | 534篇 |
内科学 | 2319篇 |
皮肤病学 | 37篇 |
神经病学 | 912篇 |
特种医学 | 365篇 |
外科学 | 1576篇 |
综合类 | 40篇 |
预防医学 | 207篇 |
眼科学 | 208篇 |
药学 | 555篇 |
中国医学 | 25篇 |
肿瘤学 | 894篇 |
出版年
2023年 | 48篇 |
2022年 | 24篇 |
2021年 | 187篇 |
2020年 | 104篇 |
2019年 | 125篇 |
2018年 | 178篇 |
2017年 | 124篇 |
2016年 | 183篇 |
2015年 | 200篇 |
2014年 | 244篇 |
2013年 | 337篇 |
2012年 | 488篇 |
2011年 | 551篇 |
2010年 | 322篇 |
2009年 | 275篇 |
2008年 | 500篇 |
2007年 | 548篇 |
2006年 | 549篇 |
2005年 | 479篇 |
2004年 | 472篇 |
2003年 | 494篇 |
2002年 | 476篇 |
2001年 | 173篇 |
2000年 | 142篇 |
1999年 | 164篇 |
1998年 | 117篇 |
1997年 | 100篇 |
1996年 | 94篇 |
1995年 | 80篇 |
1994年 | 132篇 |
1993年 | 85篇 |
1992年 | 137篇 |
1991年 | 120篇 |
1990年 | 110篇 |
1989年 | 121篇 |
1988年 | 105篇 |
1987年 | 76篇 |
1986年 | 92篇 |
1985年 | 85篇 |
1984年 | 57篇 |
1983年 | 36篇 |
1982年 | 28篇 |
1981年 | 25篇 |
1980年 | 30篇 |
1979年 | 34篇 |
1978年 | 23篇 |
1977年 | 26篇 |
1974年 | 21篇 |
1971年 | 23篇 |
1969年 | 18篇 |
排序方式: 共有9293条查询结果,搜索用时 140 毫秒
1.
Higuchi Takashi Sugisawa Norihiko Yamamoto Jun Oshiro Hiromichi Han Qinghong Yamamoto Norio Hayashi Katsuhiro Kimura Hiroaki Miwa Shinji Igarashi Kentaro Tan Yuying Kuchipudi Shreya Bouvet Michael Singh Shree Ram Tsuchiya Hiroyuki Hoffman Robert M. 《Cancer chemotherapy and pharmacology》2020,85(2):285-291
Cancer Chemotherapy and Pharmacology - Cancers are methionine (MET) and methylation addicted, causing them to be highly sensitive to MET restriction. The present study determined the efficacy of... 相似文献
2.
Keisuke Kondo Motohiro Kikuchi Daisuke Nasu Takahiro Kaneko Norio Horie 《Pediatric Dental Journal》2019,29(1):34-36
In this paper, we report two rare cases of foreign body oral injuries caused by forks inserted tightly into both sides of the lingual interdental spaces between the mandibular deciduous canines and first deciduous molars (FDMs). These pediatric cases of foreign body insertion caused not only soft tissue injuries but also the potential luxation of affected deciduous teeth, i.e., the FDMs in the present cases, during the removal of the object by force. 相似文献
3.
4.
Yusuke Kagawa Hiromi Furuta Takehiro Uemura Naohiro Watanabe Junichi Shimizu Yoshitsugu Horio Hiroaki Kuroda Yoshitaka Inaba Takeshi Kodaira Katsuhiro Masago Shiro Fujita Akio Niimi Toyoaki Hida 《Cancer science》2020,111(12):4442
Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD‐1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty‐eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. 相似文献
5.
6.
Masahito Sawahata Daisuke Mori Yuko Arioka Hisako Kubo Itaru Kushima Kanako Kitagawa Akira Sobue Emiko Shishido Mariko Sekiguchi Akiko Kodama Ryosuke Ikeda Branko Aleksic Hiroki Kimura Kanako Ishizuka Taku Nagai Kozo Kaibuchi Toshitaka Nabeshima Kiyofumi Yamada Norio Ozaki 《Psychiatry and clinical neurosciences》2020,74(5):318-327
7.
8.
9.
10.
Norio Itokawa Masanori Atsukawa Akihito Tsubota Noritomo Shimada Hidenori Toyoda Koichi Takaguchi Atsushi Hiraoka Tomonori Senoh Mai Koeda Yuji Yoshida Tomomi Okubo Taeang Arai Korenobu Hayama Ai Nakagawa-Iwashita Chisa Kondo Katsuhiko Iwakiri 《Internal medicine (Tokyo, Japan)》2021,60(4):507
Objective Pegylated-interferon monotherapy is the standard treatment for patients with chronic hepatitis B; however, the factors associated with its therapeutic effects remain unclear. Methods Patients with chronic hepatitis B were treated with pegylated interferon α-2a for 48 weeks. We evaluated the kinetics of hepatitis B surface antigen (HBsAg) during treatment and follow-up periods and the factors associated with an HBsAg response (defined as a change in HBsAg of ≥-1 log IU/mL from baseline). Results The study population comprised 50 patients. The median baseline levels of hepatitis B virus DNA and HBsAg were 5.00 and 3.40 log IU/mL. The median values of HBsAg reduction from baseline were -0.44 (n=48), -0.41 (n=40), and -0.68 (n=11) log IU/mL at the end of treatment and at 48 and 144 weeks post-treatment, respectively. The rates of HBsAg response were 24.0% and 22.5% at the end of treatment and at 48 weeks post-treatment, respectively. A multivariate analysis identified HBsAg <3.00 log IU/mL as an independent baseline factor contributing to the HBsAg response at the end of treatment and 48 weeks post-treatment (p=1.07×10-2 and 4.42×10-2, respectively). There were significant differences in the reduction of the HBsAg levels at 12 weeks of treatment and in the incidence of serum ALT increase during treatment between patients with and without an HBsAg response. Conclusion These findings suggest that the baseline HBsAg level, HBsAg kinetics at 12 weeks of treatment, and ALT increase during treatment are important factors contributing to the HBsAg response in pegylated interferon α-2a monotherapy for patients with chronic hepatitis B. 相似文献